| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.4M | +104.4% | +138.4% |
| SG&A Expense | $3.0M | +46.1% | +97.4% |
| Operating Income | -$9.4M | -81.2% | -123.5% |
| Income Tax | $0 | — | — |
| Net Income | -$8.9M | -66.5% | -225.4% |
| EPS (Basic) | -$0.27 | -50.0% | -145.5% |
| EPS (Diluted) | -$0.27 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $0 | — | — |
| Current Assets | $11.8M | +6.4% | +27.2% |
| Total Assets | $11.8M | +6.7% | +27.5% |
| Current Liabilities | $10.0M | +98.1% | +176.9% |
| Total Liabilities | $11.7M | +63.8% | +54.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.8M | — | — |
| Financing Cash Flow | $13.1M | — | — |
| -145.5% |
| $42K |
| -98.9% |
| -97.4% |